NCT06979076 2025-09-29A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLLMingSight Pharmaceuticals, IncPhase 1/2 Not yet recruiting12 enrolled